A5027295416- Viral Infections and Vectors
- Viral Infections and Outbreaks Research
- SARS-CoV-2 and COVID-19 Research
- Mosquito-borne diseases and control
- Influenza Virus Research Studies
- Vector-Borne Animal Diseases
- Hepatitis B Virus Studies
- COVID-19 Clinical Research Studies
- Viral gastroenteritis research and epidemiology
- Receptor Mechanisms and Signaling
- SARS-CoV-2 detection and testing
- Fire effects on ecosystems
- Diagnosis and treatment of tuberculosis
- Brucella: diagnosis, epidemiology, treatment
- COVID-19 epidemiological studies
- Animal Virus Infections Studies
- Neuropeptides and Animal Physiology
- Viral Infections and Immunology Research
- Health Systems, Economic Evaluations, Quality of Life
- Infectious Diseases and Tuberculosis
- Disaster Response and Management
- Salmonella and Campylobacter epidemiology
- Sepsis Diagnosis and Treatment
- Tuberculosis Research and Epidemiology
- Immune responses and vaccinations
Johns Hopkins Medicine
2015-2024
Johns Hopkins University
2015-2024
National Institute of Allergy and Infectious Diseases
2022-2024
National Institutes of Health
2023-2024
Pennsylvania State University
2013-2015
Johns Hopkins Bayview Medical Center
2015
Penn State Milton S. Hershey Medical Center
2014-2015
Shahid Beheshti University of Medical Sciences
2007-2013
MedStar Union Memorial Hospital
2011-2013
Shahid Beheshti University
2008-2013
Abstract In the PREVENT-19 phase 3 trial of NVX-CoV2373 vaccine (NCT04611802), anti-spike binding IgG concentration (spike IgG), anti-RBD (RBD and pseudovirus 50% neutralizing antibody titer (nAb ID50) measured two weeks post-dose are assessed as correlates risk protection against COVID-19. Analyses conducted in U.S. cohort baseline SARS-CoV-2 negative per-protocol participants using a case-cohort design that measures markers from all 12 recipient breakthrough COVID-19 cases starting 7 days...
We evaluated our SARS-CoV-2 prefusion spike recombinant protein vaccine (CoV2 preS dTM) with different adjuvants, unadjuvanted, and in a one-injection two-injection dosing schedule previous phase 1-2 study. Based on interim results from that study, we selected the AS03 adjuvant for further clinical development. However, lower than expected antibody responses, particularly older adults, higher reactogenicity after second vaccination were observed. In current safety immunogenicity of an...
Hyperlipidemia can lead to atherosclerosis by lipoprotein deposition inside the vessel wall and oxidative stress induction that leads formation of atherosclerotic plaque. Oxidized low-density particles (Ox-LDL) have a key role in pathogenesis atherosclerosis. The lipid-lowering properties antioxidants grape seed be beneficial prevention. We conducted randomized double-blind placebo-controlled crossover clinical trial. Fifty-two mildly hyperlipidemic individuals were divided into two groups...
Crimean-Congo hemorrhagic fever (CCHF) is a viral disease with several different modes of transmission. We describe the manifestations, outcome, and likely transmission for three nosocomial cases. All threee cases were healthcare workers (two men one woman). They had fever, myalgia, petechia. Disseminated intravascular coagulation resulted in death occurred woman. Because this manifested non-specific influenza-like symptoms, diagnosis can be difficult. Data these patients used to investigate...
We aimed to assess humoral immune response the influenza vaccine in adult kidney transplant recipients (KTRs) subjected two immunosuppressive regimens containing either mycophenolate mofetil (MMF) or azathioprine (Aza).40 eligible KTRs (24 treated with Aza [KTRs-Aza] and 16 MMF [KTRs-MMF]) 40 matched healthy controls (HCs) were administered trivalent 2006-2007 anti-influenza vaccine. Antibody (Ab) titers measured before (pre-vacc) 1 month after (post-vacc) vaccination. The proportion of...
Background/Objectives: Influenza infection is associated with cardiovascular mor-bidity and mortality, but effect of influenza vaccination on outcomes not fully understood. This clinical trial aimed to investigate correlation between car-diovascular vaccine (FluVac) in coronary artery diseases (CAD) subjects. Methods: was a randomized single blinded placebo-controlled trial. Enrolled CAD subjects received 0.5 ml 2007-2008 trivalent FluVac (15µg he-magglutinin each Solomon Islands/3/2006...
This study aimed to investigate the clinical and epidemiologic features of Crimean-Congo hemorrhagic fever among 34 children adolescents (mean age, 13.3 ± 4.6 years) from a highly endemic region. Clinical manifestations were similar those in adults. The case-fatality ratio was 26.5% (9 34). Compared with adult patients, may be more vulnerable severe fatal fever.
Abstract Several recent studies have suggested that an association exists between Helicobacter pylori (HP) eradication and improvement in platelet count a significant proportion of patients with idiopathic thrombocytopenic purpura (ITP). In this controlled study, we prospectively examined adult chronic ITP for HP infection, assessed the effect on count. One hundred forty‐two consecutive Iranian were assessed. Those who met criteria had counts >30 × 10 9 /L within medication‐free screening...
"A Call for Randomized Controlled Trials to Test the Efficacy of Chloroquine and Hydroxychloroquine as Therapeutics against Novel Coronavirus Disease (COVID-19)" published on 06 May 2020 by The American Society Tropical Medicine Hygiene.
Dengue fever (DF) is a mosquito-borne acute viral disease presenting with hemorrhagic manifestations in severe cases. Southeast Iran close proximity to Pakistan, an endemic country for DF. This cross-sectional study was conducted the Sistan and Baluchestan province southeast of investigate possibility DF (immunoglobulin M [IgM], immunoglobulin G [IgG], nonstructural protein 1 [NS1] antigen tests) 60 clinically suspected patients (April 2013 August 2015). NS1 detected 5% ( N = 3), at least...
Abstract Background COVID-19 vaccines with alternative strain compositions are needed to provide broad protection against newly emergent SARS-CoV-2 variants of concern. Methods We conducted a global Phase 3, multi-stage efficacy study ( NCT04904549 ) among adults aged ≥18 years. Participants were randomized 1:1 receive two intramuscular injections 21 days apart bivalent recombinant protein vaccine AS03-adjuvant (5 μg ancestral (D614) and 5 B.1.351 [beta] variant spike protein) or placebo....